Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment

Cancer

Volumn 120, Issue 8, 2014, Pages 1263-1271

  Resnick, Matthew J ^a,b   Barocas, Daniel A ^a   Morgans, Alicia K ^a   Phillips, Sharon E ^a   Chen, Vivien W ^c   Cooperberg, Matthew R ^d   Goodman, Michael ^e   Greenfield, Sheldon ^f   Hamilton, Ann S ^g   Hoffman, Karen E ^h   Kaplan, Sherri H ⁱ   Paddock, Lisa E ^j   Stroup, Antoinette M ^k   Wu, Xiao Cheng ^c   Koyama, Tatsuki ^a   Penson, David F ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j New Jersey State Cancer Registry   (United States)

^k RUTGERS UNIVERSITY   (United States)

more..

Author keywords

bowel function; prostate cancer; quality of life; sexual function; urinary function

Indexed keywords

ADULT; AGE; AGED; ARTICLE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOCRINE DISEASE; ENTEROPATHY; ERECTILE DYSFUNCTION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEN'S HEALTH; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; URINE INCONTINENCE;

BOWEL FUNCTION; PROSTATE CANCER; QUALITY OF LIFE; SEXUAL FUNCTION; URINARY FUNCTION;

AGE FACTORS; AGED; COHORT STUDIES; COMORBIDITY; ERECTILE DYSFUNCTION; HORMONES; HUMANS; INTESTINAL DISEASES; LINEAR MODELS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; URINARY INCONTINENCE;

EID: 84898046739     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28563     Document Type: Article

References (29)

1. Zeliadt SB, Moinpour CM, Blough DK, et al. Preliminary treatment considerations among men with newly diagnosed prostate cancer [serial online]. Am J Manag Care. 2010; 16: e121-e130.
2. Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose 1 treatment over another? A review of patient decision making for localized prostate cancer. Cancer. 2006; 106: 1865-1874.
3. Holmboe ES, Concato J,. Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med. 2000; 15: 694-701.
4. Feldman-Stewart D, Brundage MD, Van Manen L, Svenson O,. Patient-focused decision-making in early-stage prostate cancer: insights from a cognitively based decision aid. Health Expect. 2004; 7: 126-141.
5. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
6. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS,. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009; 101: 888-892.
7. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013; 368: 436-445.
8. Johansson E, Steineck G, Holmberg L, et al. for the SPCG-4 Investigators. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011: 12; 891-899.
9. Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011; 306: 1205-1214.
10. Freedman, DS,; Centers for Disease Control and Prevention (CDC), Obesity-United States, 1988-2008. MMWR Surveill Summ. 2011; 60 (suppl): 73-77.
11. Geiss, LS, Li, Y, Kirtland, K, et al. Centers for Disease Control and Prevention (CDC). Increasing prevalence of diagnosed diabetes-United States and Puerto Rico, 1995-2010. MMWR Morbidity and Mortality Weekly Reports. 2012; 61: 918-921.
12. Seftel AD, Sun P, Swindle R,. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol. 2004; 171: 2341-2345.
13. Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ,; Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med. 2006; 166: 207-212.
14. Lubeck DP, Litwin MS, Henning JM, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996; 48: 773-777.
15. Barocas DA, Chen V, Cooperberg M, et al. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res. 2013; 2: 445-460.
16. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG,. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000; 56: 899-905.
17. Szymanski KM, Wei JT, Dunn RL, Sanda MG,. Development and validation of an abbreviated version of the Expanded Prostate Cancer Index Composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010; 76: 1245-1250.
18. Litwin MS, Greenfield S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH,. Assessment of prognosis with the Total Illness Burden Index for Prostate Cancer: aiding clinicians in treatment choice. Cancer. 2007; 109: 1777-1783.
19. Markland AD, Richter HE, Fwu C-W, Eggers P, Kusek JW,. Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008. J Urol. 2011; 186: 589-593.
20. Litwin MS,. Health related quality of life in older men without prostate cancer. J Urol. 1999; 161: 1180-1184.
21. Erickson BA, Vaughan-Sarrazin M, Liu X, Breyer BN, Kreder KJ, Cram P,. Lower urinary tract symptoms and diet quality: findings from the 2000-2001 National Health and Nutrition Examination Survey. Urology. 2012; 79: 1262-1267.
22. Litwin MS, McGuigan KA,. Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol. 1999; 17: 2882-2888.
23. Fransson P, Damber J-E, Widmark A,. Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer. Scand J Urol Nephrol. 2009; 43: 119-126.
24. Legler J, Potosky AL, Gilliland FD, Eley JW, Stanford JL,. Validation study of retrospective recall of disease-targeted function: results from the Prostate Cancer Outcomes Study. Med Care. 2000; 38: 847-857.
25. Wilt TJ, Brawer MK, Jones KM, et al. Prostate Cancer Intervention Versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367: 203-213.
26. Bill-Axelson A, Holmberg L, Ruutu M, et al. SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011; 364: 1708-1717.
27. Juniper EF, Guyatt GH, Willan A, Griffith LE,. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994; 47: 81-87.
28. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA,. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993; 20: 557-560.
29. Norman GR, Sloan JA, Wyrwich KW,. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41: 582-592.